Flagship Harbor Advisors LLC Boosts Holdings in IQVIA Holdings Inc. $IQV

Flagship Harbor Advisors LLC raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 199.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,502 shares of the medical research company’s stock after acquiring an additional 3,662 shares during the quarter. Flagship Harbor Advisors LLC’s holdings in IQVIA were worth $867,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Canada Pension Plan Investment Board increased its holdings in IQVIA by 7.3% during the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock valued at $810,069,000 after acquiring an additional 312,807 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in IQVIA by 45.7% during the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after acquiring an additional 798,534 shares in the last quarter. Nordea Investment Management AB increased its holdings in IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after acquiring an additional 606,391 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of IQVIA by 26.8% during the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock worth $253,695,000 after buying an additional 304,258 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of IQVIA by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company’s stock worth $251,852,000 after buying an additional 40,699 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

IQVIA stock opened at $216.30 on Friday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $225.91. The firm has a 50 day moving average price of $196.62 and a 200 day moving average price of $173.32. The company has a market cap of $36.77 billion, a price-to-earnings ratio of 29.67, a PEG ratio of 2.39 and a beta of 1.32. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.84 and a current ratio of 0.70.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same period in the previous year, the firm earned $2.84 earnings per share. IQVIA’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Redburn Partners set a $214.00 price target on shares of IQVIA in a report on Wednesday, September 3rd. Citigroup lifted their price target on shares of IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a report on Wednesday. Truist Financial reiterated a “buy” rating and set a $265.00 price target (up from $235.00) on shares of IQVIA in a report on Wednesday. Finally, HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $244.48.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.